Deans' stroke musings: Intranasal drug delivery disruptor OptiNose signs licensing deal for migraine treatment

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, July 4, 2013

Intranasal drug delivery disruptor OptiNose signs licensing deal for migraine treatment

And maybe we'll finally get enough exposure to the nasal drug delivery route that our doctors and researchers can use to bypass the blood brain barrier.
We have to point out this possibility to our doctors, we're 7 million strong and eventually our doctors will realize that we actually know more than they do.
http://medcitynews.com/2013/07/intranasal-drug-delivery-disruptor-optinose-signs-licensing-deal-for-migraine-treatment/?utm_source=MedCity+News+Subscribers&utm_campaign=ff607c7578-RSS_Daily+Top+Stories&utm_medium=email&utm_term=0_c05cce483a-ff607c7578-67013357
A few paragraphs, more at link.
Longterm, OptiNose sees its approach to drug delivery as improving treatment for central nervous system disorders because of the possibility its technology could be used to overcome the blood brain barrier, according to its website. It also believes its technology could be sued for vaccines.
Greg Flesher, senior vice president of corporate development of Avanir Pharmaceuticals said in a company statement: “OptiNose has developed a unique device that has the potential to transform the clinical profile of the leading migraine drug, resulting in a new product candidate that we believe can significantly improve upon the current treatment options.”